Amicus Therapeutics Inc

Amicus Therapeutics — Q2 2022 Earnings Presentation

24 slides from Amicus Therapeutics's earnings presentation, Aug 4, 2022

  1. Slide 1: 2Q22 Financial Results Conference Call & Webcast

    2Q22 Financial Results Conference Call & Webcast August 4, 2022 At the Forefront of Therapies for Rare Diseases

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and

  3. Slide 3: A Rare Company

    3 A Rare Company Patient-dedicated, Rare Disease Biotechnology Company with Sustained Double-digit Revenue Growth, a Global Commercial Infrastructure, and Late-stage Development Capabilities AT-GAA a Two-component Therapy Under Global Regulatory Reviews for Pompe Disease GLOBAL COMMERCIAL ORGANIZATI

  4. Slide 4: Positioned for Significant Value Growth

    4 Positioned for Significant Value Growth Focused on Execution and Driving Sustainable Double-digit Revenue Growth on Path to Profitability Continue to bring Galafold® to as many patients as possible, sustain double-digit revenue growth Successful launch of AT-GAA for people living with Pompe diseas

  5. Slide 5: 2022 Strategic Priorities to Drive Value

    2022 Strategic Priorities to Drive Value 1 2 3 4 5 Double-digit Galafold growth (15-20%) with revenue of $350M to $365M at CER1 Secure FDA approval and positive CHMP opinion for AT-GAA Initiate successful, rapid launch in U.S. for AT-GAA Advance best-in-class, next-generation genetic medicines and c

  6. Slide 6: Galafold (migalastat) Continued Growth

    6 Galafold® (migalastat) Continued Growth... … building a leadership position in the treatment of Fabry disease

  7. Slide 7: Galafold Success (as of June 30, 2022)

    7 Galafold Success (as of June 30, 2022) Building on Galafold’s Success and Leveraging Leadership Position to Drive Continued Growth Galafold is indicated for adults with a confirmed diagnosis of Fabry Disease and an amenable variant. The most common adverse reactions reported with Galafold (≥10%) w

  8. Slide 8: Galafold Performance

    8 Galafold Performance 1H22 Reported Revenue Growth of +10.9% to $159.4M - Operational Growth of +17.8% at CER .. Global 3-month net new patients trend greater than 6-month and 12-month .. In the U.S., the month of June saw highest net new patients and PRFs since April 2021 .. Global mix of switch (

  9. Slide 9: Galafold Success and FY22 Revenue Guidance

    9 Galafold Success and FY22 Revenue Guidance Galafold Momentum on Track to Achieve Full-year 2022 Revenue Guidance at CER FY16 FY17 FY18 FY19 FY20 FY21 FY22 $5.0M Q1 $78.7M Q2 $80.7M $36.9M $91.2M $182.2M $260.9M $305.5M 12022 Galafold revenue guidance utilizes the average actual rates for 2021 H1 $

  10. Slide 10: Galafold Growth Opportunity

    10 Penetration of the diagnosed untreated population Increase in newborn screening and diagnostic initiatives Strong IP rights, including COM protection through 2038 Continued penetration into existing markets Expansion into new geographies Broadening of labels Galafold Growth Opportunity $1B Annual

  11. Slide 11: AT-GAA (cipaglucosidase alfa + miglustat)

    11 AT-GAA (cipaglucosidase alfa + miglustat) … potential to establish a new standard of care for people living with Pompe disease

  12. Slide 12: AT-GAA Launch Preparations

    12 AT-GAA Launch Preparations Experienced and Passionate Rare Disease Medical and Commercial Organization Poised for Second Successful Launch Key Strengths Commitment to patient access Clear focus on launch Identification of key Pompe disease treatment centers Development of educational materials Pl

  13. Slide 13: Pompe Disease Overview

    13 Deficiency of GAA leading to lysosomal glycogen accumulation and cellular dysfunction Age of onset ranges from infancy to adulthood Symptoms include muscle weakness, respiratory failure, and cardiomyopathy Respiratory and cardiac failure are leading causes of morbidity and mortality Estimated inc

  14. Slide 14: Phase 3 PROPEL Study Results

    14 Phase 3 PROPEL Study Results Overall Population (n=122*) Primary and First Key Secondary Endpoint Showed Greater Improvement with AT-GAA vs. alglucosidase alfa in the Overall Population of ERT-Naïve and ERT-Experienced Patients 6MWD=6-minute walk distance;; FVC=forced vital capacity; SE=standard

  15. Slide 15: Long-Term Data from Phase 1/2 Clinical Study (ATB200-02)

    15 Long-Term Data from Phase 1/2 Clinical Study (ATB200-02) Persistent and Durable Improvements in Motor and Respiratory Function and Reductions in Biomarkers of Muscle Damage and Disease Substrate Observed in Patients out to 36 Months NOTE: * One patient in the ERT-naïve cohort experienced a large

  16. Slide 16: AT-GAA: Key Takeaways

    16 AT-GAA: Key Takeaways .. Regulatory status update: – U.S. PDUFA date 2H20221 – CHMP opinion late 2022 – Planning for additional regulatory submissions .. Multiple expanded access mechanisms in place, including in the U.S., U.K., Germany, France, Japan, and others – First reimbursed access through

  17. Slide 17: Amicus Pipeline

    17 INDICATION DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL FABRY FRANCHISE Galafold®(migalastat) Fabry Gene Therapy Next-Generation Chaperone POMPE FRANCHISE AT-GAA (cipaglucosidase alfa + miglustat) Pompe Gene Therapy OTHER CLN3 Batten Disease Gene Therapy Next-Generation Research

  18. Slide 18: Financial & Operational Strategy

    18 Financial & Operational Strategy … maintaining a strong financial outlook

  19. Slide 19: Revenue Performance

    19 Revenue Performance Q2 Revenue Growth of +4.3% to $80.7M resulting from Strong Operational Growth of +12.9% at CER Offset by Negative FX impact of -8.6% $77.4M $80.7M -8.6% +12.9% 2Q21 Operational Growth FX Impact 2Q22 Year-over-Year Sales Growth .. Significant currency exposure as 66% of Galafol

  20. Slide 20: 2Q Select Financial Results

    20 2Q Select Financial Results 2Q22 OpEx Increase Reflects Manufacturing Costs to Support AT-GAA Launch and Non-Recurring Expenses Related to the Reprioritization of the Gene Therapy Portfolio Jun. 30, 2022 (in thousands, except per share data) Jun. 30, 2021 Product Revenue $80,731 $77,413 Cost of G

  21. Slide 21: Financial Outlook and Path to Profitability

    Financial Outlook and Path to Profitability Clear Strategy to Build Our Business, Advance Our Portfolio, and Achieve Profitability 21 Sustain Galafold Revenue Growth Deliver on Financial Goals Secure Approvals of AT-GAA $159.4M 1H2022 revenue, +17.8% YoY Operational Growth 2022 Galafold revenue guid

  22. Slide 22: Thank You

    A ba AMICUS Thank You

  23. Slide 23: Appendix

    ° A WCcus AM endix p Ap

  24. Slide 24: Reconciliation of Non-GAAP Financial Measures

    Appendix Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands) Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Total operating expenses - as reported GAAP $133,147 $107,867 3 279,619 $3 220,785 Research and development: Share-based compensat

Amicus Therapeutics — Q2 2022 Earnings Presentation on 6ix